Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is common with an annual incidence of 1 per 1,000 in Caucasian adults 1 and results in a major burden to the healthcare system. The mainstay of treatment for VTE over recent decades has been initial anticoagulation with heparin or low-molecular-weight heparin (LMWH) followed by vitamin K antagonist (VKA).
The non-vitamin K antagonist oral anticoagulants (NOACs) have provided an effective, safe, and convenient alternative to VKA, 2 which has led to their increasing use.
3
Rivaroxaban, a factor Xa inhibitor, is approved as monotherapy for the initial treatment of acute VTE. This has simplified the treatment of patients with acute VTE and facilitated early discharge from hospital. Anticoagulants, including NOACs, remain the most common drug class implicated in adverse drug-related events prompting presentations to emergency departments (ED). 4 Data from the phase 3 clinical trials comparing the safety and efficacy of NOACs to VKA/LMWH have shown that rates of bleeding and VTE recurrence are highest during the first few weeks of anticoagulation therapy, [5] [6] [7] [8] [9] [10] highlighting the potential benefit of careful patient monitoring early during the anticoagulation period.
Although the use of VKAs with daily injections of LMWH and international normalized ratio (INR) monitoring provided opportunities for early detection and prevention of adverse events because of the regular contact with health care professionals, such "informal" monitoring has been significantly reduced with the NOACs. Although randomized trials showed favorable outcomes with the use of NOACs, commencement of NOAC therapy can be problematic outside of the controlled environment of clinical trials. Indeed published surveys report up to a third of hospital patients may receive an incorrect dose or are inappropriately prescribed a NOAC even when contraindicated.
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The International Society on Thrombosis and Haemostasis (ISTH) 15 and European Heart Rhythm Association (EHRA) 16 provide practical guidance on the use of NOACs, emphasizing the need for appropriate patient selection, minimizing unnecessary drug-drug interactions, and monitoring for dosing errors, adherence, or adverse effects. Several models of care for the optimal follow-up and clinical monitoring of patients receiving therapy with NOACs have been proposed, 17 but there are currently no published studies evaluating the effectiveness of a nurse-led approach. Monash Health, a major university metropolitan health service in Victoria, Australia, provides acute inpatient services at four campuses. Rivaroxaban was the first NOAC in Australia to receive approval for the treatment of VTE (August 2013) and was the only government-subsidized NOAC available for this indication in 2015 when our pathway was initiated. The overall aim for our pathway was to facilitate the safe transition of patients with VTE treated with rivaroxaban into the community. Our pragmatic pathway was designed to be coordinated by an experienced anticoagulation nurse with oversight by experienced hematologists, and to provide broad access to all patients within the large geographical area covered by our health service. We used simple and inexpensive methods of communication such as telephone contact and text messaging to achieve this goal.
The aims of this study were to report on (1) the proportion of patients who were identified as at risk for adverse events (i.e., bleeding or recurrence) using prespecified criteria, (2) the proportion of patients requiring interventions, and (3) the clinical outcomes (bleeding and recurrent thrombosis) of patients who were prospectively followed up and managed through our nurse-led postdischarge pathway.
Methods Study Design and Participants
We prospectively followed up a cohort of consecutive patients with objectively confirmed acute VTE, who were enrolled in the rivaroxaban VTE treatment pathway between July 28, 2015, and May 31, 2017. This project was approved as a quality and service improvement project (reference number RES-17-0000-196Q). Patients were identified by screening pharmacy discharge scripts, inpatient admissions/consultations, referrals to the hematology outpatient clinic, or by ED discharge summaries. Patients were eligible for inclusion if they were at least 18 years of age, with objectively confirmed acute VTE and who were initiated on rivaroxaban. Patients with superficial vein thrombosis/or venous thrombosis in any vascular territory were included in our definition of VTE. Exclusion criterion was anticoagulation for other indications, for example, stroke prevention for atrial fibrillation or thromboprophylaxis post-hip/knee arthroplasty.
Study Procedures/Data Collection
An overview of the pathway is shown in ►Fig. 1. In brief, an experienced research nurse (AC) extracted relevant clinical and laboratory information for review by the anticoagulation team within 10 to 14 days of discharge. The team consisted of the research nurse, one hematology fellow, and two hematologists. Subsequently, patients were followed up by the study nurse with telephone calls and/or text messaging at 14, 21, 35, 45, and 90 days to monitor for any bleeding, VTE recurrence, patient adherence, appropriate dosing, concomitant medications, and laboratory parameters. These data were recorded on prespecified checklists at each contact (►Supplementary Fig. S1 , online only). Duration of follow-up was up to 90 days or until end of treatment or death whichever came earlier. A patient information kit was also mailed within a week of the first telephone call, containing a rivaroxaban information booklet; an emergency contact card; and a laboratory request form for complete blood count (CBC), urea, electrolytes and creatinine (UEC), and liver function test (LFT). Patients on the pathway were routinely reviewed as an outpatient within 30 to 60 days.
If a patient was identified as being at risk of bleeding or recurrent thrombosis, then appropriate measures (interventions) were undertaken to mitigate their risk of harm. Most interventions, where deemed appropriate, were performed by telephone instructions to the patient, their family, family physician, or pharmacist to minimize need for healthcare facility visits. However, clinical review or ED visits were organized when required.
Study Outcomes
The primary outcome was the proportion of patients at major risk of bleeding or VTE recurrence post-hospital discharge using prespecified criteria. These criteria were based on the exclusion criteria and recommended doses used in the pivotal phase 3 trials evaluating use of rivaroxaban for acute VTE treatment (►Table 1). 5, 6 Secondary outcomes were (1) the proportion of patients with other prespecified risk factors for bleeding/ recurrence, (2) proportion of patients requiring major or minor interventions, and (3) rates of major or clinically relevant nonmajor bleeding (CRNMB), objectively confirmed recurrent VTE, all-cause mortality, and non-bleeding-related rehospitalization at 90 days from the time of enrolment into the study.
Study Definitions
Major bleeding and CRNMB were as defined by the ISTH.
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Recurrent VTE was defined as new or progression of thrombus from baseline ultrasound for DVT or new/extension of filling defects on computed tomography pulmonary angiogram (CTPA) or new mismatches on ventilation-perfusion (VQ) scan in a patient with new or worsening symptoms. A major intervention was any intervention requiring unscheduled inpatient admission/ED attendance or clinic review.
Minor interventions were any other interventions not requiring hospital/clinic visit. Interventions were categorized according to hospital resource utilization but not necessarily weighted by their clinical importance. For example, if the nurse identified a patient taking an incorrect dose of rivaroxaban, this patient was deemed at "major risk" for an adverse event, but if this was managed by simple telephone instructions or provision of a new prescription, the intervention was considered "minor" despite the potential for significant harm to the patient. Minimum baseline bloods were defined as CBC, serum creatinine, LFTs, and routine coagulation testing (activated partial thromboplastin time, INR, and fibrinogen level) prior to commencement of rivaroxaban. Creatinine clearance (CrCl) was based on the Cockcroft Gault equation using actual body weight.
Statistical Analysis
Descriptive statistics were used to analyze patient demographics and baseline data using Microsoft Excel 2013. Categorical variables are expressed as frequency and percentage with 95% confidence interval (CI); continuous variables are expressed as mean and standard deviation. The 95% CIs of proportions were calculated using the Wilson Score method (online calculator available at http://epitools.ausvet.com.au/ content.php).
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Results

Characteristics of Study Cohort
Between July 28, 2015, and May 31, 2017, a total of 341 patients were identified in the pathway. After exclusion of 10 patients, 331 patients were eligible for analysis of primary and secondary outcomes (►Fig. 2). The pathway had to be suspended from December 15, 2016, to January 31, 2017, due to an illness in a member of the study team. During this period, 27 patients were identified but not followed up according to the study protocol timelines and therefore were excluded in the analysis. However, their follow-up outcomes are available and are reported separately (►Supplementary Table S1 , online only).
Of the 304 patients included, median age was 56 years with equal proportions of males and females. PE (with or without DVT) was diagnosed in 178 (58.5%) patients, 53 (17.4%) patients had a proximal DVT, and 62 (20.4%) had a distal DVT. Other indications for anticoagulation were upper limb DVT (n ¼ 5), superficial vein thrombosis (n ¼ 4), internal jugular vein thrombosis (n ¼ 1), and portal vein thrombosis (n ¼ 1). Hereditary thrombophilia was not routinely evaluated. However, 16 patients had documented thrombophilia (12 heterozygous FV Leiden mutation, 1 antithrombin deficiency, 1 homozygous prothrombin mutation, 1 protein C deficiency, and 1 heterozygous prothrombin mutation). Baseline characteristics of the patients are shown in ►Table 2.
Treatment and Follow-up
At 90 days, a total of 257 patients (85%) remained on anticoagulation. Of these, 231 (74%) remained on rivaroxaban therapy and 26 (10%) were switched from rivaroxaban to another anticoagulant (warfarin n ¼ 4, enoxaparin n ¼ 11, apixaban n ¼ 11). The most common reasons for switching were concerns regarding bleeding or recurrence (►Supplementary Table S2 , online only). In the other 47 patients, follow-up was less than 90 days due to death (n ¼ 5) or treatment cessation earlier than 90 days (n ¼ 34 for distal DVT; n ¼ 3 for superficial vein thrombosis, and n ¼ 5 for proximal DVT/PE). Patients with PE or proximal DVT were on anticoagulant therapy for a median of 90 days (interquartile range [IQR]: 90-90 days), whereas patients with isolated distal DVT were on anticoagulant therapy for a median of 86 days (IQR: 47.5-90 days). All 304 patients were followed up to 90 days or until the end of treatment or death whichever occurred earlier. 
Primary Outcome
Fifteen of 304 patients (4.9%; 95% CI: 3.0-8.0) were identified to be at major risk of bleeding or recurrence. The most common major risks identified in patients were nonadherence (n ¼ 2) and taking a higher or lower than recommended dose of rivaroxaban (n ¼ 9; ►Table 3).
Secondary Outcomes
Proportion of patients with prespecified possible risk factors for bleeding or recurrence: Twenty-eight patients (9.3%) were identified with prespecified possible risk factors for bleeding/recurrence including patients with previous gastrointestinal (GI) bleeding (n ¼ 2), young women with known menorrhagia (n ¼ 6), or patients with a body mass index (BMI) of greater than 40 or weight greater than 120 kg (n ¼ 14; ►Table 3).
Proportion of Patients with Interventions
Interventions were required for 167 patients in the entire cohort (54.9%; 95% CI: 49.3-60.4). Of the 43 patients with prespecified criteria, 40 had interventions of which 6 were major and 34 were minor. None of the patients with prespecified major risk factors suffered recurrent VTE or bleeding after appropriate interventions were instituted. Of the 28 patients with prespecified possible risk factors, recurrence was diagnosed in 1 patient with increased BMI of 42 and CRNMB occurred in 9 patients. The majority (five of nine) of these patients with CRNMB had worsening of preexisting menorrhagia (►Supplementary Table S2 , online only). An additional 127 patients had interventions outside of prespecified criteria of which 8 were major and 119 were minor (►Supplementary Table S3 , online only). Twenty-eight patients were on concomitant medications that could increase the risk of bleeding including antiplatelet agents (n ¼ 21) or fish oil, an inhibitor of platelet aggregation (n ¼ 7). In patients on antiplatelets without clear indication (n ¼ 12) or fish oil (n ¼ 7), it was recommended to the patients or their general practitioner for these to be ceased to minimize the risk of bleeding.
Clinical Outcomes
Bleeding: Major bleeding occurred in one patient (0.3%; 95% CI: 0.1-1.8), who suffered from an upper GI bleed. CRNMB was observed in 22 patients (7.2%; 95% CI: 4.8-10.7). The most common sites of CRNMB bleeding were genitourinary (n ¼ 10) and GI (n ¼ 6). Most bleeding events (15/23, 65%) occurred in the first month of anticoagulation (►Supplementary Fig. S2 , online only). Recurrent VTE: Recurrent VTE occurred in three patients (1.0%; 95% CI: 0.3-2.9). All three cases of possible VTE recurrences occurred after the first month (►Supplementary Fig. S3 , online only). Two patients had distal DVT recurrences while on rivaroxaban (for PE and distal DVT, respectively). One patient was diagnosed with a "new" PE on VQ scan 3 weeks after rivaroxaban was discontinued based on a nondiagnostic scan and was recommenced on anticoagulation by the treating clinicians without further definitive investigations. There were no patients with fatal PE.
Mortality: The incidence of all-cause mortality was 5 of 304 (1.6%; 95% CI: 0.7-3.8%). This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Rehospitalization: Rehospitalization occurred in 22 of 304 (7.2%; 95% CI: 4.8-10.7). Five patients (1.6%) required hospital admission due to bleeding/VTE recurrence, while the other 17 patients were admitted for other reasons.
Discussion
Our study demonstrates that at least 1 in 7 (43 of 304) patients prescribed rivaroxaban for acute VTE are at major or possible risk of adverse events following initiation of rivaroxaban in hospital. By early postdischarge identification of these "at-risk" patients, we were able to initiate appropriate interventions, which in the majority of patients entailed reinforcing medication adherence, clarifying the appropriate dosage, or occasionally switching anticoagulation therapy. We showed that these simple and timely interventions, coupled with an active program of regular monitoring using telephone calls and text-messaging reminders, were associated with low rates of major bleeding or recurrent VTE. Although examples of nurse-led VTE post-discharge pathway care have been described previously, 20 to our knowledge, this is the first prospective study to comprehensively report on outcomes and the associated interventions in patients with acute VTE taking rivaroxaban.
Rates of Bleeding and VTE Recurrence
The rate of major bleeding (0.3%; 95% CI: 0.1-1.8) with our nurse-led pathway is among the lowest reported in other observational studies. These studies reported rates of major bleeding which vary between 0.5 and 4% (►Table 5).
5,6,21-27
Higher rates of major bleeding (4.1% per annum) were observed in the Dresden registry 21 compared with the XALIA (XA inhibition with rivaroxaban for Long-term and Initial Anticoagulation in venous thromboembolism) study,
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which had lower rates of bleeding (1.2% per annum). This difference is partly explained by younger patients in the XALIA study (74 vs. 59 years) and a lower proportion with impaired renal function (11 vs. 4% had glomerular filtration rate or CrCl < 50 mL/min). However, another potential explanation is that unlike the Dresden registry, patients in XALIA were managed by experienced clinicians with a structured follow-up. Taken together, this suggests that appropriate patient selection and a post-discharge clinical monitoring are important to maximize the safety and efficacy benefits of rivaroxaban in clinical practice.
Risk Factors for Bleeding or Recurrence
In our study, we identified 3% (10 of 304) of patients who were prescribed or taking the incorrect dose of rivaroxaban. However, this has been reported to be as high as 10 to 20% in other studies. 13, 28, 29 We demonstrated that these patients could be identified quickly through our nurse-led pathway and that timely corrective action and education were easily instituted by telephone. Major bleeding occurred in one patient secondary to an upper GI bleed due to gastric erosions. This patient had a history of iron deficiency for which multiple GI endoscopies had not identified a source of bleeding. She was switched empirically to apixaban 4 weeks previously (in view of nonspecific abdominal pain while taking rivaroxaban), which was discontinued at the time of the bleed. After bleeding had stabilized, the patient was commenced on enoxaparin.
Five of six women who presented with CRNMB secondary to heavy menstrual bleeding had a history of menorrhagia. Given the reported association of abnormal uterine bleeding with rivaroxaban, 30, 31 we specifically counseled these women on the risk of worsening menstrual bleeding and gave them the option to switch to anticoagulation but most (three of five) declined. Subsequent to the heavy menstrual bleeding episode, these women chose to switch to an alternative agent (apixaban or warfarin).
Feasibility of Our Nurse-Led Postdischarge Pathway
Our experience with this nurse-led pathway suggests that it is easy to implement, requiring minimal resources and personnel (one nurse and access to support from two to three specialist hematologists as required). Most of our interventions (153 of 167, 90%) were minor, including those used (34 of 40, 85%) to address prespecified major risk factors for bleeding or recurrence. By using readily available and inexpensive communication tools such as telephone and text messaging, we were able to minimize travel time and expenses for both clinicians and patients while enabling follow-up to be kept on schedule, thus allowing for timely contact and intervention if required.
Strengths and Limitations
Our study has several strengths. First, our cohort consists of consecutive patients in a large university hospital setting, and is thus representative of "real-world" patients. We used prespecified criteria to identify patients at risk of bleeding/ VTE recurrence for which an intervention was indicated, thus limiting case-finding bias and to ascertain our primary and secondary outcomes. All patients were prospectively Nurse-Led Rivaroxaban Pathway for VTE Patients Lim et al. 193
followed up as part of the pathway to the end of their course of anticoagulation or up to 90 days, thus minimizing bias introduced by loss to follow-up. There are several limitations to our study. First, there was no comparator group; however, we showed that our clinical outcome data are comparable to phase 3 clinical trials and XALIA where patients were managed by experienced staff and were closely monitored. The low rates of bleeding in our study are likely biased by only including patients and the corresponding events that occurred post discharge when patients were identified in the pathway. However, this was the intended purpose of our study and despite this, a significant number of patients were still identified to be at major risk for bleeding or recurrence post discharge. Six patients had CRNMB between hospital discharge and first contact, all of which were reported to the nurse. Of these patients, major interventions were initiated in three patients: two had unscheduled clinic review and one patient was asked to present to emergency. While it is possible that some adverse events between discharge and the initial contact (day 12 AE 4 from initiation of rivaroxaban) may have occurred and were not reported, we are confident that these data would have been captured as all patients were specifically asked by the nurse about any bleeding or symptoms of recurrence according to our prespecified checklist (►Supplementary Fig. S2 , online only) and this was verified by checking the electronic medical records for any hospital presentations which may have occurred.
Conclusion
A nurse-led pathway for early postdischarge review and monitoring of patients with acute VTE initiated on rivaroxaban identified one in seven patients with VTE discharged on rivaroxaban who were at major or possible risk of bleeding or recurrence. Early identification and appropriate interventions in these patients likely contributed to the overall low rates of major bleeding and VTE recurrence in the entire cohort. Our experience highlights the feasibility and the potential benefits of an early nurse-led clinical surveillance pathway for patients with acute VTE starting NOAC therapy. Contributions S. Chunilal and A. Cummins were involved in the conception and design of the project. M.S. Lim, T. Indran, and A. Cummins were involved in data acquisition. M.S. Lim, S. Chunilal, and N. C. Chan were involved in data analysis and interpretation. M. S. Lim wrote the first draft of the manuscript. All authors contributed to critical revision of the manuscript and approved the final version of the manuscript.
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